Next Article in Journal
Role of Tibial Tuberosity Fracture/Fissure through the Maquet Hole in Stifle Osteoarthritis after Porous Tibial Tuberosity Advancement in Dogs at Mid-Term Follow-Up
Previous Article in Journal
Clove Oil Delays Rather Than Prevents Scur/Horn Growth in Dairy Cattle
Open AccessCase Report

Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs

1
Eye Center for Animals Inc., 524 Moss Street, New Orleans, LA 70119, USA
2
Animal Eye Guys, Fort Lauderdale, Florida, FL 33308, USA
3
Organ, Tissue, Regeneration, Repair and Replacement Company (OTR3), F-75001 Paris, France
4
Laboratoire Croissance, Régénération, Réparation et Régénération Tissulaires (CRRET), EAC CNRS 7149, University Paris Est Creteil, F-94010 Créteil, France
*
Author to whom correspondence should be addressed.
Vet. Sci. 2019, 6(4), 103; https://doi.org/10.3390/vetsci6040103
Received: 13 November 2019 / Revised: 10 December 2019 / Accepted: 11 December 2019 / Published: 13 December 2019
(This article belongs to the Section Clinical Veterinary Medicine)
Superficial corneal ulcers that fail to heal within a normal time period and are refractory to conventional therapy in dogs are common in veterinary practice. Different etiologies can lead to this result, including spontaneous chronic corneal epithelial defects (SCCEDs) and ulcerative keratitis associated with bullous keratopathy. Thus, there is an urgent need to find new therapeutic approaches such as matrix therapy replacement. To determine the efficacy of a new ophthalmic treatment (Clerapliq®) for SCCEDs and ulcerative keratitis associated with bullous keratopathy, a total of 11 dogs referred to the clinic because of nonhealing erosive ulcers after a classic primary treatment were enrolled to get this new treatment. Dogs underwent ophthalmic exams and 7 dogs (10 eyes) were diagnosed with superficial ulceration and 4 dogs (5 eyes) with bullous keratopathy due to endothelial dystrophy/degeneration. They received eye drops of Clerapliq® every 3 days until recovery. The results showed that the corneas with recurrences of the ulcers were resolved predominantly by using Clerapliq® every 3 days in 83.3% of the cases during a period of treatment ranging between 6 to 35 days. Therefore, this new approach using matrix therapy regenerating technology in treating superficial ulcers and bullous keratopathy in dogs can be successfully considered as an adjunctive therapy. View Full-Text
Keywords: regenerative medicine; Clerapliq®; regenerating agent; ophthalmology; otr4120 regenerative medicine; Clerapliq®; regenerating agent; ophthalmology; otr4120
Show Figures

Figure 1

MDPI and ACS Style

Martinez, J.A.; Chiappini, F.; Barritault, D. Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs. Vet. Sci. 2019, 6, 103.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop